Adenocarcinoma In Situ — Trials

Adenocarcinoma In Situ — Trials · CancerIndex

Clinical trials

Registered studies

210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 61
Recruiting: 31
Ph III recruiting: 3
Growth YoY: —
Industry share: 5%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (32)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07762885	Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery	recruiting	Phase 3	636	Fudan UniversityOTHER	1	Aug 13, 2026	clinicaltrials
NCT04422366	Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females	recruiting	Phase 3	8,000	Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY	1	Jun 7, 2024	clinicaltrials